Search research articles
Contact Us
Filters
Showing results (61-70 of 107) with videos related to
Page
of 11
Sort By:
International Journal of Hematology
|
December 27, 2023
Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
Shinichi Makita, Shuichi Ota, Yuko Mishima, et al.
Annals of Hematology
|
November 16, 2017
Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance
Yoshiharu Kusano, Masahiro Yokoyama, Norihito Inoue, et al.
International Journal of Hematology
|
September 1, 2020
The clonal evolution during long-term clinical course of multiple myeloma
Yuko Mishima, Yuji Mishima, Yuko Shirouchi, et al.
Haematologica
|
September 28, 2014
Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma
Hideaki Nitta, Yasuhito Terui, Masahiro Yokoyama, et al.
Leukemia & Lymphoma
|
March 22, 2021
Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with <i>de novo</i> diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma
Hideki Uryu, Yuko Mishima, Naoko Tsuyama, et al.
International Journal of Hematology
|
September 5, 2023
Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
Shinsuke Iida, Kazutaka Sunami, Yuko Mishima, et al.
International Journal of Hematology
|
November 2, 2019
Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
Kazuhito Suzuki, Nobuhiro Tsukada, Noriko Nishimura, et al.
Japanese Journal of Clinical Oncology
|
July 24, 2023
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Wataru Munakata, Koji Izutsu, Yuko Mishima, et al.
Journal of Clinical Gastroenterology
|
February 18, 2011
Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis
Norihisa Ishimura, Yuji Amano, Alvaro Adolfo Sanchez-Siles, et al.
ISRN Oncology
|
May 22, 2013
Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
Masahiro Yokoyama, Yasuhito Terui, Kengo Takeuchi, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 107) with videos related to
Sort By:
Page
of 11
International Journal of Hematology
|
December 27, 2023
Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
Shinichi Makita, Shuichi Ota, Yuko Mishima, et al.
Annals of Hematology
|
November 16, 2017
Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance
Yoshiharu Kusano, Masahiro Yokoyama, Norihito Inoue, et al.
International Journal of Hematology
|
September 1, 2020
The clonal evolution during long-term clinical course of multiple myeloma
Yuko Mishima, Yuji Mishima, Yuko Shirouchi, et al.
Haematologica
|
September 28, 2014
Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma
Hideaki Nitta, Yasuhito Terui, Masahiro Yokoyama, et al.
Leukemia & Lymphoma
|
March 22, 2021
Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with <i>de novo</i> diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma
Hideki Uryu, Yuko Mishima, Naoko Tsuyama, et al.
International Journal of Hematology
|
September 5, 2023
Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
Shinsuke Iida, Kazutaka Sunami, Yuko Mishima, et al.
International Journal of Hematology
|
November 2, 2019
Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
Kazuhito Suzuki, Nobuhiro Tsukada, Noriko Nishimura, et al.
Japanese Journal of Clinical Oncology
|
July 24, 2023
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Wataru Munakata, Koji Izutsu, Yuko Mishima, et al.
Journal of Clinical Gastroenterology
|
February 18, 2011
Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis
Norihisa Ishimura, Yuji Amano, Alvaro Adolfo Sanchez-Siles, et al.
ISRN Oncology
|
May 22, 2013
Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
Masahiro Yokoyama, Yasuhito Terui, Kengo Takeuchi, et al.
Page
of 11